MRK
NYSE · Pharmaceuticals
Merck & Co. Inc.
$111.38
-0.92 (-0.82%)
MRK News30 articles
Dow Jones Slips Below 50,000 as Chip Stocks Drag, Focus Shifts to Jobs Data
The Dow Jones Industrial Average fell below 50,000 on Thursday as chip stocks retreated and investors awaited the monthly jobs report.
Summit Therapeutics Shares Dive 23% After HARMONi-3 Update Disappoints
Summit Therapeutics shares plummeted 23% after an interim HARMONi-3 update for ivonescimab failed to show early benefit. The trial remains blinded, with final PFS data due in late 2026.
Dow Falls as Tariffs Weigh on Blue-Chips, Tech Lifts S&P and Nasdaq
Dow Jones fell 78 points Friday as EU auto tariff worries offset Apple's strong earnings. S&P 500 and Nasdaq hit new highs on tech gains.
Tempus AI Faces Pivotal May with Q1 Results and Inaugural Investor Day
Tempus AI reports Q1 results May 5 and holds its first investor day May 29, with Merck CEO highlighting the partnership. Stock trades near $55.44 with a $9.7B market cap.
Pfizer Gains on FDA Priority Review for Padcev as Pipeline Pivots Post-COVID
Pfizer shares advanced after the FDA granted priority review for its Padcev bladder cancer therapy, setting an August decision. Investors await Q1 results to gauge progress in oncology and obesity drugs against fading COVID sales.
SCHD ETF Approaches 52-Week Peak as Dividend Strategies Regain Favor
The Schwab U.S. Dividend Equity ETF traded near $31.06, close to its 52-week high, with year-to-date gains around 14%. The fund captured a significant portion of the $24.1 billion that flowed into U.S. dividend funds during the first quarter.
SCHD ETF Sees Strong Q1 Inflows After Dividend Hike and Portfolio Overhaul
The Schwab U.S. Dividend Equity ETF (SCHD) reported a 3.3% dividend increase and $4 billion in first-quarter inflows following a significant portfolio reshuffle that boosted healthcare and tech exposure while reducing energy holdings.
SCHD ETF Boosts Healthcare in Rebalance as Dividend Fund Inflows Surge
The Schwab U.S. Dividend Equity ETF (SCHD) increased its healthcare allocation to 18.5% during its yearly portfolio update, adding Abbott Laboratories and UnitedHealth Group. The fund gathered nearly $4 billion in the first quarter as investors poured a total of $24.1 billion into U.S. dividend-focused funds, marking the strongest quarterly start since 2022.
Merck's $6.7B Terns Buyout Anchors Stock Near Offer Price
Merck has agreed to acquire Terns Pharmaceuticals in a $6.7 billion all-cash deal. Terns shares traded at $52.86, close to Merck's $53-per-share offer, as investors weigh the deal's completion.
Merck Acquires Terns Pharma in $6.7B Deal to Fortify Cancer Portfolio
Merck will purchase Terns Pharmaceuticals for $53 per share in cash, a transaction valued at approximately $6.7 billion. The acquisition provides Merck with an experimental leukemia therapy as it prepares for the loss of exclusivity for its blockbuster drug Keytruda.
SCHD ETF Gains Investor Attention Following Annual Rebalance and Dividend Payout
The Schwab U.S. Dividend Equity ETF (SCHD) is drawing renewed interest following its annual portfolio rebalance and a recent dividend distribution. The fund's strategic shift and income profile are being highlighted as key attractions for investors.
ImmunityBio Plunges 21% on FDA Warning Over Anktiva Marketing
ImmunityBio shares tumbled 21.1% following an FDA warning letter alleging false or misleading promotional claims about its cancer therapy Anktiva. The drug generated essentially all of the company's $113 million in 2025 revenue.
J&J Shares Dip on Lupus Drug Fast Track, Investors Eye Legal Risks
Johnson & Johnson shares declined 0.7% to $245.07 Wednesday after the FDA granted Fast Track designation to its lupus drug candidate nipocalimab, lagging behind a strong market advance.
ImmunityBio Shares Dip Ahead of Key Business Update Call
ImmunityBio shares edged lower in premarket activity Tuesday, giving back some of the prior session's gains ahead of a scheduled business update and full-year results call later in the day.
Merck's Keytruda, Welireg Data and FDA Dates Drive Stock Momentum
Merck stock gained after reporting Phase 3 survival data for Keytruda in ovarian and kidney cancers. The FDA set 2026 review dates for Welireg combinations.
Merck Shares Rally on Keytruda-Welireg Kidney Cancer Data, Gardasil Job Cuts
Merck shares gained nearly 4% Friday following new clinical data for its Keytruda and Welireg combination in kidney cancer, alongside announced workforce reductions at a Gardasil vaccine facility.
Healthcare ETF Rises on Dexcom, Moderna Earnings; Markets Eye Holiday
Healthcare stocks advanced Friday, with the XLV ETF rising 1.1% as Dexcom and Moderna posted strong quarterly results. U.S. markets are closed Monday for the Presidents Day holiday.
Merck Shares Surge to 52-Week High on Deutsche Bank Upgrade
Merck shares climbed to a 52-week high following an upgrade from Deutsche Bank, which raised its price target to $150. The company is set to present new bladder and kidney cancer data later this month.
Moderna Shares Rise on Q4 Beat, Flu Vaccine Faces FDA Hurdle
Moderna shares advanced roughly 5% late Friday after reporting better-than-expected Q4 revenue. The company reaffirmed its 2026 growth targets despite an FDA setback for its seasonal flu vaccine.
Merck Shares Gain on Deutsche Bank Upgrade Ahead of Key Cancer Data
Merck shares advanced following a Deutsche Bank upgrade to Buy and a raised price target, with investors focused on upcoming oncology data at the ASCO GU symposium.
Merck Shares Dip Following Insider Transactions Amid Revenue Forecast Concerns
Merck shares declined 0.5% after SEC filings revealed stock sales by two executives, adding pressure following a revenue outlook that fell short of analyst expectations.
ImmunityBio Shares Stabilize After 15% Surge, Focus Turns to Upcoming Earnings
ImmunityBio's stock held steady near $7 in premarket trading following a sharp 14.6% rally. Investors are now awaiting the company's quarterly results, due in early March.
Dow Futures Edge Higher Ahead of Key Economic Data Releases
Dow Jones futures advanced slightly Tuesday as investors await retail sales figures, with payroll and inflation reports due later this week. Tech stocks led Monday's market recovery.
Merck Shares Drop on Insider Sale, Investors Await Key FDA Decision
Merck & Co. stock fell 3.5% amid an executive share sale and underperformance versus a broader market rally. Traders are focused on an upcoming FDA ruling for Keytruda's ovarian cancer expansion.
Dow Holds 50,000 as Markets Await Key Jobs, Inflation Data
The Dow Jones Industrial Average edged up 17 points to 50,132.79, maintaining its position above the 50,000 threshold. Investors are focused on upcoming employment and inflation reports, which could influence Federal Reserve policy.
Merck Shares Slide 4% on Patent Concerns and 2026 Outlook
Merck & Co. stock fell nearly 4% Monday, underperforming the broader market as investors reacted to projected patent losses and a cautious 2026 sales forecast.
Dow Retreats from 50K Milestone as Investors Await Inflation, Jobs Data
The Dow Jones Industrial Average edged lower Monday after its historic close above 50,000, while the S&P 500 and Nasdaq gained on tech strength. Markets are focused on upcoming inflation and employment reports.
Johnson & Johnson Shares Retreat Amid Healthcare Sector Weakness
Johnson & Johnson stock declined 1.1% as healthcare stocks underperformed the broader market. Traders are eyeing upcoming U.S. jobs and inflation data for direction.
Dow Retreats Below 50,000 as Rotation Hits Tech; Key Economic Data Awaited
The Dow Jones Industrial Average fell below the 50,000 mark in Monday trading, pressured by a shift out of technology stocks. Investors await critical payrolls and inflation reports later this week.
Merck Nears 52-Week Peak Amid Insider Sale, Investors Eye Pipeline Updates
Merck shares climbed 1.8% to $121.93, extending gains for a seventh session and approaching a 52-week high. An executive sold 37,685 shares as investors await the impact of 2026 guidance and pipeline developments.